Strides Pharma Science Share Price Today | Stock Price & Strides Pharma Science Share Screener
As of October 5, 2026, the live Strides Pharma Science share price (NSE: STAR) is ₹1,086.70 on NSE and ₹1,085.85 on BSE, up 0.18% from the previous close, with shares trading between ₹1,077.60 and ₹1,109.90 in today's trading session, and a 52-week range of ₹793.55–₹1,235.10. Check STAR 52-week performance for the annual price range and momentum. Use the Strides Pharma Science stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Strides Pharma Science opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹1,333 and net income of ₹129, with EBITDA of ₹243, an operating margin of 18.0% and a profit margin of 9.7%.
Strides Pharma Science Share Price Chart
Track the current stock price of Strides Pharma Science with an interactive chart. Analyse STAR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Strides Pharma Science stock quote in one place.
The quote of ₹1,086.70 sits between the 52-week low of ₹793.55 and the 52-week high of ₹1,235.10, and the latest session moved 0.18% from the previous close.
Strides Pharma Science Company Profile - Fundamental Screener
Screen Strides Pharma Science company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for STAR shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE939A01011.
Company Details
Classification
Identifiers and Leadership
Strides Pharma Science Balance Sheet Screener
Screen STAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹6,927, up from ₹6,049 in 2025.
Latest statistics put total assets at ₹6,927 and shareholder funds at ₹3,149, with a leverage ratio of 0.64.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 6,927 | 6,049 | 5,840 | 6,638 | 6,976 | 7,015 | 6,152 | 7,980 | 6,708 | 8,105 |
| Current Assets | 3,613 | 3,099 | 2,969 | 3,243 | 3,362 | 2,817 | 2,372 | 3,049 | 2,484 | 3,792 |
| Fixed Assets | 2,101 | 1,899 | 1,865 | 2,311 | 2,347 | 2,219 | 2,099 | 3,648 | 2,977 | 2,980 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 882 | 871 | 889 | 1,475 | 1,181 | 1,463 | 1,012 | 2,516 | 2,191 | 2,119 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 3,149 | 2,587 | 2,072 | 2,173 | 2,383 | 2,814 | 2,595 | 2,802 | 2,618 | 2,882 |
| Share Capital | 92 | 92 | 92 | 90 | 90 | 90 | 90 | 90 | 90 | 89 |
| Reserves & Surplus | 3,015 | 2,460 | 2,034 | 2,105 | 2,269 | 2,687 | 2,438 | 2,559 | 2,374 | 2,659 |
Strides Pharma Science Income Statement Screener - Profit & Revenue Analysis
Screen Strides Pharma Science income statement and profit fundamentals. Analyze STAR quarterly results. Strides Pharma Science reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹1,333 and net profit was ₹129, equal to earnings per unit of ₹13.77, at an operating margin of 18%.
In that period expenses were ₹1,090, interest cost ₹42 and tax ₹19. The next period listed, 2026-Jun, shows revenue of ₹1,334 and net profit of ₹166.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 1,333 | 1,334 | 1,206 | 1,128 | 1,248 | 1,302 | 1,030 | 4,354 | 1,195 | 1,160 | 1,014 | 939 | 1,035 | 1,075 | 952 |
| Expenses | 1,090 | 1,037 | 1,000 | 910 | 999 | 962 | 888 | 866 | 987 | 946 | 879 | 802 | 1,054 | 886 | 944 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 243 | 297 | 206 | 218 | 249 | 340 | 142 | 3,488 | 209 | 215 | 135 | 136 | -18 | 189 | 8 |
| Operating Profit % | 18.00% | 18.00% | 16.00% | 19.00% | 18.00% | 19.00% | 15.00% | 18.00% | 15.00% | 18.00% | 11.00% | 14.00% | -5.00% | 12.00% | -9.00% |
| Depreciation | 53 | 56 | 49 | 49 | 50 | 51 | 48 | 47 | 49 | 48 | 61 | 60 | 60 | 49 | 61 |
| Interest | 42 | 41 | 50 | 48 | 46 | 43 | 71 | 73 | 74 | 52 | 81 | 76 | 79 | 70 | 50 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 148 | 200 | 106 | 122 | 153 | 246 | 23 | 3,369 | 86 | 114 | -7 | 0 | -157 | 70 | -103 |
| Tax | 19 | 34 | 21 | 17 | 22 | 37 | 13 | 19 | 14 | 24 | 7 | 10 | -7 | 16 | -132 |
| Net Profit | 129 | 166 | 86 | 106 | 132 | 208 | 10 | 3,350 | 72 | 90 | -14 | -9 | -150 | 54 | 29 |
| EPS | 13.77 | 17.02 | 8.92 | 10.81 | 13.84 | 21.93 | 1.98 | 364.64 | 7.81 | 9.56 | -1.06 | -0.79 | -14.54 | 5.43 | 3.25 |
Strides Pharma Science Cash Flow Screener - Liquidity Fundamentals
Screen STAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹703, and net cash flow was an inflow of ₹76.
Over the same period, investing activities used ₹173 and financing activities used ₹453.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 703 | 684 | 701 | 44 | -258 | 481 | 205 | 60 | 187 | 288 |
| Investing Activities | -173 | -90 | -150 | 302 | -119 | -522 | 1,321 | -145 | 570 | -1,222 |
Financing and Net Cash | ||||||||||
| Financing Activities | -453 | -643 | -693 | -214 | 421 | -16 | -1,709 | 194 | -1,016 | 338 |
| Net Cash Flow | 76 | -49 | -143 | 133 | 45 | -56 | -184 | 110 | -259 | -596 |
Strides Pharma Science Shareholding Pattern Screener
See Strides Pharma Science shareholding pattern with promoter, FII, and DII holdings. Check Strides Pharma Science promoter holding and ownership changes for STAR on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 27.91%, foreign institutions 28.39%, domestic institutions 15.41% and the public 20.42%, spread across 94,856 shareholders.
The shareholder count was 94,856 in 2026-Jun, compared with 86,616 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 27.91% | 27.91% | 27.86% | 27.86% | 28.30% | 28.30% | 26.82% | 25.84% |
Institutional Investors | ||||||||
| FII Holding | 28.39% | 28.68% | 29.52% | 28.51% | 28.02% | 28.32% | 28.48% | 30.08% |
| DII Holding | 15.41% | 14.45% | 13.02% | 12.98% | 13.30% | 13.72% | 16.92% | 18.24% |
Government, Public and Others | ||||||||
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 20.42% | 20.78% | 21.42% | 22.44% | 22.10% | 21.52% | 20.86% | 18.57% |
| Other Holding | 7.85% | 8.17% | 8.17% | 8.20% | 8.27% | 8.14% | 6.90% | 7.26% |
| Shareholder Count | 94,856 | 86,616 | 85,589 | 91,206 | 92,889 | 95,125 | 114,236 | 96,009 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Strides Pharma Science. Strides Pharma Science dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹5.00 per unit for 2026-March, a yield of 0.46%, compared with ₹4.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹5.00, ₹4.00 and ₹2.50 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹5.00 | 0.46% |
| 2025-March | ₹4.00 | 0.43% |
| 2024-March | ₹2.50 | 0.37% |
| 2023-March | ₹1.50 | 0.19% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹2.50 | 0.72% |
| 2020-March | ₹14.00 | 1.66% |
| 2019-March | ₹3.00 | 0.93% |
| 2018-March | ₹2.00 | 0.42% |
| 2017-March | ₹4.50 | 0.69% |
Strides Pharma Science Stock Index Membership - Nifty & Sensex
See which indices include Strides Pharma Science stock. Check STAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 5 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.
Complete Index List
Strides Pharma Science Market Events Screener - Corporate Actions
Get Strides Pharma Science corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Strides Pharma Science stock events that may affect STAR share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated August 14, 2026, with a record date of August 14, 2026.
It is followed by Quarterly Result Announcement dated July 31, 2026 and Dividend dated July 31, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-14 | 2026-08-14 | Annual General Meeting | NA | -8.59% |
| 2026-07-31 | 2026-07-31 | Quarterly Result Announcement | NA | 4.15% |
| 2026-07-31 | 2026-07-31 | Dividend | ₹ 5.00 /share | -6.98% |
| 2026-05-18 | 2026-05-18 | Quarterly Result Announcement | NA | -0.16% |
| 2026-01-30 | 2026-01-30 | Quarterly Result Announcement | NA | -6.46% |
| 2025-10-31 | 2025-10-31 | Quarterly Result Announcement | NA | 3.90% |
| 2025-08-07 | 2025-08-07 | Annual General Meeting | NA | -6.92% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | 5.08% |
| 2025-07-22 | 2025-07-22 | Dividend | ₹ 4.00 /share | 28.02% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | 4.76% |
| 2025-01-30 | 2025-01-30 | Quarterly Result Announcement | NA | -3.10% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -5.07% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | 2.29% |
| 2024-09-10 | 2024-09-10 | Extraordinary General Meeting | NA | 17.24% |
| 2024-09-09 | 2024-09-09 | Dividend | ₹ 2.50 /share | 60.77% |
Strides Pharma Science Competitors Screener - Peer Stocks Comparison
Screen STAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,010 | 35.84 | 61,674 | 12.69% | 11,565 | 33.78 |
| Divis Laboratories | 244,125 | 84.36 | 11,067 | 13.95% | 2,568 | 49.73 |
| Torrent Pharmaceuticals | 181,512 | 84.01 | 13,886 | 20.34% | 2,138 | 41.48 |
| Zydus Life Science | 113,616 | 24.88 | 27,658 | 17.64% | 5,026 | 46.18 |
| Cipla | 107,890 | 32.42 | 29,045 | 2.24% | 3,870 | 32.87 |
| Laurus Labs | 106,517 | 98.56 | 6,868 | 22.01% | 890 | 56.11 |
| Mankind Pharma | 102,394 | 50.48 | 14,636 | 14.85% | 1,938 | 55.53 |
| Dr Reddys Laboratories | 100,412 | 31.47 | 35,059 | 3.90% | 4,158 | 52.91 |
| Aurobindo Pharma | 96,370 | 25.97 | 34,145 | 5.56% | 3,503 | 49.89 |
| Lupin | 91,961 | 16.71 | 29,039 | 26.75% | 5,356 | 29.12 |
Strides Pharma Science Company Announcements - News & Reports Screener
Screen STAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 24, 2026.
The next most recent announcements are dated September 23, 2026 and September 11, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-24 | Closure of Trading Window | - |
| 2026-09-23 | Strides Sustainability Report For FY26 | - |
| 2026-09-11 | Completion Of USFDA Inspection At The Companys Formulations Facility At Alathur | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-18 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-14 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-31 | Outcome Of Board Meeting Of The Company Held On July 31 2026 | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-24 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30 2026 Amongst Other Matters. | - |
| 2026-07-21 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-07-21 | Notice Of 35Th Annual General Meeting | - |
| 2026-07-21 | Reg. 34 (1) Annual Report. | - |
| 2026-07-20 | Company Has Fixed The Record Date For Final Dividend For FY26 As Friday July 31 2026 | - |
| 2026-07-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-03 | Announcement under Regulation 30 (LODR)-Restructuring | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,086.70, within a 52-week range of ₹793.55 to ₹1,235.10. The P/E ratio is 15.73 and the P/B ratio is 3.21, with earnings per unit of ₹60.34. Market capitalisation stands at ₹10,016.41 Cr and the dividend yield is 0.46%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.